Back
Bicara Therapeutics 10K Form
Sell
20
BCAX
Bicara Therapeutics
Last Price:
18.08
Seasonality Move:
--
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive BCAX News And Ratings
See the #1 stock for the next 7 days that we like better than BCAX
BCAX Financial Statistics
Sales & Book Value
| Annual Sales: | -- |
|---|---|
| Cash Flow: | $0 |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-3.80 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -0.20230 |
|---|---|
| Net Income (TTM): | $-64.84M |
| Gross Margin: | -- |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Bicara Therapeutics Earnings Forecast
Key Bicara Therapeutics Financial Ratios
- The Interest Expense is 0.00% of Operating Income.
- Per Share Earnings over the last 2 years have been positive in 0 years.
Bicara Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | BCAX |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
BCAX Technical Analysis vs Fundamental Analysis
Sell
20
Bicara Therapeutics (BCAX)
is a Sell
Is Bicara Therapeutics a Buy or a Sell?
-
Bicara Therapeutics stock is rated a Sell
The current Bicara Therapeutics [BCAX] share price is $18.09. The Score for BCAX is 20, which is 60% below its historic median score of 50, and infers higher risk than normal.